Clinical Trials · NCT07466017
A Study of CS060380 Tablets in Patients With MASH and Obesity
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- Cascade Pharmaceuticals, Inc
- Enrollment
- 130
- Start date
- Apr 2026
- Locations
- 12 sites, China
- Primary endpoint
- Percentage change in liver fat content from baseline to Week 36 (MRI-PDFF)